GSK is still ... vaccination against RSV in older adults, the larger market opportunity, but falling behind Pfizer in maternal immunisation is a blow to the prospects of a development programme ...

The reversal from the Advisory Committee on Immunization Practices (ACIP) is a potential boost for GSK and Pfizer. Both companies saw sales of their RSV vaccines for adults tumble last year after ...

GSK has become the first pharma ... identified a protein in RSV a decade ago that looked like a promising antigen for vaccine development. Both Arexvy and Abrysvo target this PreF protein, as ...

which would represent a positive surprise for GSK, in our view.” While Moderna (MRNA) has an FDA-approved RSV vaccine, its messenger-RNA-based shot is only approved by the FDA for those aged 60 ...

In GSK’s suit against Pfizer, the British pharma was seeking monetary damages or royalties and potentially a permanent injunction on the commercialization of Pfizer’s RSV vaccine in the U.S.

GSK (GSK) said it is “pleased” that the Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines including GSK’s AREXVY in adults aged 50-59 who ...

GSK) on Thursday agreed to end a patent lawsuit over claims that the former’s vaccine, Abrysvo for respiratory syncytial virus (RSV) allegedly violated the British pharma giant’s patent rights ...

GSK filed suit in August 2023, alleging that Pfizer’s respiratory syncytial virus (“RSV”) vaccine, ABRYSVO, infringes four U.S. patents covering GSK’s rival RSV vaccine, AVREXY.

GSK said in the lawsuit that Pfizer began working on its RSV program around 2013, at least seven years after GSK began developing its shot. Pfizer denied the allegations and argued GSK's patents ...